Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Equillium Inc

USUSD
← Allo Screener
US:EQLSE:0A4D

Equillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'Azienda

Sito Web
equilliumbio.com
Settore
Health Care · Biotechnology: Pharmaceutical Preparations
Sede Centrale
LA JOLLA, United States
Amministratore Delegato
Bruce Steel
Dipendenti
14
Azioni in Circolazione
63.41 Mln al 2026-08-07
Flottante
36.97 Mln
Capitalizzazione di Mercato
89.41 Mln USD
Insider
16%
Investitori Istituzionali
65.76%
Settore (SIC)
Pharmaceutical Preparations
P/E
perdita
FCF
−20.1 Mln USD
Debito
7.64 Mln USD
liquidità netta
Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

pubblicità

Borse e Ticker

BorsaTickerValutaPrezzoTipo
US USA StocksEQ principaleUSD1.32 -12.00%azioni ordinarie
LSE London Stock Exchange0A4D IOBUSD1.4 +0.00%azioni ordinarie

Prezzo su 3 Mesi

giorno di rialzo giorno di ribassoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo

Principali Azionisti

DetentoreQuotaAzioniData del Rapporto
Jupiter Topco LLC10.24%6.49 Mln2026-06-30
Decheng Capital LLC7.01%4.45 Mln2026-06-30
Affinity Asset Advisors,…6.47%4.1 Mln2026-06-30
Adar1 Capital Management…5.93%3.76 Mln2026-06-30
Aberdeen Group plc5.73%3.63 Mln2026-06-30
abrdn Life Sciences Inve…5.73%3.63 Mln2026-06-30
Woodline Partners LP5.52%3.5 Mln2026-06-30
RA Capital Management, L…4.88%3.1 Mln2026-06-30
Stempoint Capital LP3.18%2.02 Mln2026-06-30
Vanguard Capital Managem…2.87%1.82 Mln2026-06-30
Eversept Partners, LP2.4%1.52 Mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%1.4 Mln2026-06-30
CONNELLY STEPHEN (Presid…≈1.2%762 0252026-06-05
VANGUARD INDEX FUNDS-Van…0.54%344 4892026-06-30
Fidelity Concord Street…0.26%162 8512026-07-31
iShares Trust-iShares Mi…0.24%153 0762026-08-31
American Century ETF Tru…0.12%75 4112026-08-31
ZEDELMAYER CHRISTINE (Ch…≈0.1%62 5862026-06-05
Fidelity Concord Street…0.09%54 6772026-07-31
Fidelity Concord Street…0.07%47 4652026-07-31
Invesco Exch-Trd Fd. TRT…0.06%38 5162026-08-31
Fidelity Concord Street…0.06%36 6832026-07-31
TOM PENNY (Officer)—02026-05-28
KEYES JASON A (Chief Fin…——2025-01-23